Your browser doesn't support javascript.
Ponatinib-Associated Cutaneous Eruptions-A Case Series and Review of Clinicopathologic Findings.
Weber, Isaac; Gloss, Catherine; Castillo, Brianna; Smith, Emily.
  • Weber I; School of Medicine, University of Missouri, Columbia, MO.
  • Gloss C; Department of Dermatology, University of Missouri, Columbia, MO; and.
  • Castillo B; Department of Dermatology, University of Missouri, Columbia, MO; and.
  • Smith E; Departments of Pathology and Dermatology, Michigan Medicine, Ann Arbor, MI.
Am J Dermatopathol ; 45(1): 64-68, 2023 Jan 01.
Article in English | MEDLINE | ID: covidwho-2305584
ABSTRACT
ABSTRACT Ponatinib is a third-generation tyrosine kinase inhibitor used to treat chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Cutaneous toxicities are a commonly reported side effect of ponatinib treatment with "rash" being one of the most common. Specific subtypes are infrequently reported, but include hyperkeratotic, folliculocentric, ichthyosiform, and pityriasis rubra pilaris-like eruptions. Herein, we highlight the clinicopathologic features of 2 cases of ponatinib-induced pityriasis rubra pilaris-like eruptions. We also classify the clinical and histopathologic features of all previously reported ponatinib-associated eruptions in the literature and discuss treatment and potential diagnostic pitfalls.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pityriasis Rubra Pilaris / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Exanthema / Precursor Cell Lymphoblastic Leukemia-Lymphoma Type of study: Prognostic study Limits: Humans Language: English Journal: Am J Dermatopathol Year: 2023 Document Type: Article Affiliation country: DAD.0000000000002344

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pityriasis Rubra Pilaris / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Exanthema / Precursor Cell Lymphoblastic Leukemia-Lymphoma Type of study: Prognostic study Limits: Humans Language: English Journal: Am J Dermatopathol Year: 2023 Document Type: Article Affiliation country: DAD.0000000000002344